CN115531450A - Neck application medicine for autoimmune thyroid disease and preparation process thereof - Google Patents
Neck application medicine for autoimmune thyroid disease and preparation process thereof Download PDFInfo
- Publication number
- CN115531450A CN115531450A CN202211243083.8A CN202211243083A CN115531450A CN 115531450 A CN115531450 A CN 115531450A CN 202211243083 A CN202211243083 A CN 202211243083A CN 115531450 A CN115531450 A CN 115531450A
- Authority
- CN
- China
- Prior art keywords
- parts
- neck
- raw materials
- fine powder
- autoimmune thyroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 208000010928 autoimmune thyroid disease Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001816 cooling Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 5
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 5
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 5
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 5
- 239000002671 adjuvant Substances 0.000 claims abstract description 5
- 239000010446 mirabilite Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000012545 processing Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 5
- 239000008159 sesame oil Substances 0.000 claims description 4
- 235000011803 sesame oil Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 23
- 210000001685 thyroid gland Anatomy 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 208000009453 Thyroid Nodule Diseases 0.000 abstract description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 206010040925 Skin striae Diseases 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010018498 Goitre Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 201000003872 goiter Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004412 Benign neoplasm of thyroid gland Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000003153 askanazy cell Anatomy 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a neck application medicine for autoimmune thyroid diseases and a preparation process thereof, wherein the neck application medicine is prepared from the following raw materials in a compatibility manner: 25 to 35 parts of indigo naturalis, 25 to 35 parts of peach kernel, 15 to 25 parts of borneol, 5 to 15 parts of mirabilite, 25 to 35 parts of herba lycopi and 25 to 35 parts of dandelion; taking the raw materials of the medicinal materials according to the proportion, processing the raw materials into fine powder and mixing the fine powder; heating adjuvants to 120 deg.C, filtering, and cooling to 60 deg.C at room temperature; adding the fine powder into the cooling auxiliary material, and uniformly stirring to obtain a semi-solidified paste. The medicine raw materials are easy to obtain, and the side effect is small; the prescription is externally applied on the skin on the surface of the neck, reaches striae of skin, dredges channels and collaterals and regulates qi and blood, thereby having a treatment effect on the thyroid gland; aiming at the main pathogenesis of thyroid nodule, the borneol skin penetration enhancer is added specially to take effect of the medicament penetrating into all channels, so that the treatment effect is improved, and the effective time is shortened.
Description
Technical Field
The invention belongs to the technical field of Qianban thyroiditis treatment medicines, and particularly relates to an application medicine for neck of autoimmune thyroid diseases and a preparation process thereof.
Background
Hashimoto's thyroiditis is also known as chronic lymphocytic thyroiditis and lymphocytic goiter, and was first reported by Hashimoto (1912) in japan based on histological features, and is also known as Hashimoto's thyroiditis. In the 50 s Fromm (1953) found that the serum gamma globulin level was increased, and Roitt et al (1956) detected thyroid autoantibodies in the serum of patients, suggesting that this disease may be a result of an autoimmune reaction, and chronic lymphocytic thyroiditis is also called autoimmune thyroiditis later.
The hashimoto's disease is an organ-specific autoimmune disease, the pathogenesis of which is not completely elucidated, and may be caused by the occurrence of congenital immune surveillance defect on the basis of genetic susceptibility, resulting in immune dysfunction, and the generation of humoral immunity and cellular immune response aiming at thyroid gland, so that the destruction of thyroid follicular epithelium causes diseases, and the intensity of autoimmune response is closely related to the disease condition.
The general inspection of thyroid gland mostly shows diffuse swelling, tough texture or rubber-like, nodular surface, clear edge, complete envelope and no adhesion. The microscopic examination shows that the lymphocyte and the plasma cell in the pathological thyroid tissue are in diffuse infiltration. After gland destruction, on the one hand, a new follicle is formed in a compensatory manner, and on the other hand, the destroyed gland also has an action of stimulating immunity and promoting proliferation of lymphocytes, so that a lymphatic follicle having a germinal center is formed in the thyroid gland. Thyroid epithelial cells have different stage forms, and have partial follicular hyperplasia in the early stage and much colloid in follicular cavities; as the lesion progresses, the follicle becomes smaller and shrinks, the glia in the cavity decreases, the epithelial cells swell and increase, the cytoplasm shows a marked eosinophilic staining reaction called as Askanazy cells or hurthle cells, and then the cells lose normal morphology, the follicular structure is destroyed, the stroma has fibrous tissue hyperplasia, and the space is formed, and the envelope is not affected by the lesion.
At present, the western medicine treatment of benign thyroid nodules mainly comprises TSH inhibitor treatment, I treatment, laser ablation, surgical excision and the like, and the treatment effect is not ideal. The history of treating goiter and tumor in traditional Chinese medicine is long, the traditional Chinese medicine has better curative effect on thyroid nodule, at present, oral medicines are mainly used for treatment, and medicines for clearing heat, eliminating phlegm, softening hardness and dissipating stagnation are mainly used, but the medicines are easy to injure spleen and stomach and are not suitable for long-term administration. Therefore, the joint treatment of thyroid nodules by combining external application medicaments is very necessary.
The existing research shows that: indigo naturalis improves hashimoto thyroiditis by adjusting the levels of TGAb, TPOAb, IL-10 and IFN-gamma of model rats; the application of indigo naturalis for treating HT can improve curative effect and effectively reduce autoimmune antibody index of thyroid gland.
Therefore, the application medicine for the neck of the autoimmune thyroid disease and the preparation process thereof are provided.
Disclosure of Invention
In order to solve the technical problems, the invention designs the neck application medicine for autoimmune thyroid diseases and the preparation process thereof,
in order to achieve the technical effects, the invention is realized by the following technical scheme: the indigo naturalis goiter-eliminating patch is characterized by comprising the following raw materials in parts by mass: 25 to 35 parts of indigo naturalis, 25 to 35 parts of peach kernel, 15 to 25 parts of borneol, 5 to 15 parts of mirabilite, 25 to 35 parts of herba lycopi and 25 to 35 parts of dandelion.
Further, the indigo naturalis goiter eliminating patch is prepared from the following raw materials in parts by weight: 30 parts of indigo naturalis, 30 parts of peach kernel, 20 parts of borneol, 10 parts of mirabilite, 30 parts of herba lycopi and 30 parts of dandelion.
The invention also aims to provide a preparation process of the natural indigo cecidity eliminating paste, which is characterized by comprising the following steps:
step1: taking the raw materials of the medicinal materials according to the proportion, processing the raw materials into fine powder and mixing the fine powder, wherein the borneol is independently ground into fine powder;
step2: heating adjuvants to 120 deg.C, filtering, and cooling to 60 deg.C at room temperature; mixing the auxiliary materials with the medicinal raw materials in a weight ratio of 1;
step3: adding the fine powder mixed in Step1 into the cooling auxiliary materials in Step3, and uniformly stirring to obtain a semi-solidified paste.
Further, the auxiliary materials comprise sesame oil.
The invention also aims to provide application of the natural indigo cecidity eliminating paste in the technical field of Qiao Ben thyroiditis treatment medicines.
The beneficial effects of the invention are:
indigo naturalis is cold in nature, salty in flavor, entering liver meridian, and has effects of clearing heat and detoxicating, cooling blood and resolving macula, purging pathogenic fire and arresting convulsion; the borneol has the functions of clearing heat and removing toxicity, preventing corrosion and promoting granulation, mainly disperses stagnated fire, can penetrate bone heat, and is easy to absorb through mucosa and subcutaneous tissues; semen Persicae has effects of promoting blood circulation and removing blood stasis; natrii sulfas has effects of clearing heat and softening hard masses; the application has oily property and is easy to penetrate skin; the 'goiter-eliminating paste' can clear fire and activate blood circulation, and aims at liver fire caused by liver depression and negative emotions such as excessive fire, ministerial fire, anxiety, depression and the like caused by the loss of essence and qi of a human body after staying up all night due to living disorder.
The raw materials of the medicine are common traditional Chinese medicines, are easy to obtain and have small side effect; the prescription is externally applied on the skin on the surface of the neck, reaches the striae, is used for dredging the channels and collaterals and regulating qi and blood, thereby having the treatment effect on the thyroid gland; aiming at the main pathogenesis of thyroid nodule, the borneol skin penetration enhancer is added specially to take effect of the medicament penetrating into all channels, so that the treatment effect is improved, and the effective time is shortened.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the description below are only some embodiments of the present invention, and it is obvious for those skilled in the art that other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a pathological section of thyroid tissue.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Processing indigo naturalis 9g, semen Persicae 9g, borneolum Syntheticum 6g, natrii sulfas 3g, herba Lycopi 9g, and herba Taraxaci 9g into fine powder, and mixing; heating 22.5g of sesame oil to 120 ℃, filtering, and cooling to 60 ℃ at room temperature; adding the mixed fine powder into the cooled sesame oil, and uniformly stirring to obtain a semi-solidified paste.
Example 2
Animal experiments:
SD female rats 30 are adaptively fed for 1 week, 10 rats are randomly selected as normal control groups according to body mass, and the rest rats are artificial modules. The rats in the model group were administered 0.005% iodine-enriched water (concentration: 50 mg/L) from week 2, and the rats in the normal control group were administered distilled water. After the 4 th week, the porcine thyroglobulin was fully emulsified with Freund's complete adjuvant and then injected subcutaneously into bilateral hind paw of the rats in the model group in a water-in-oil form (TG: CFA = 1: 1) in multiple injection at intervals of 2 days for 2 times, and 100. Mu.g of TG was administered to each rat at each time as the primary immunization. Subcutaneous multiple injections were performed in the rat backs at week 5, with 100. Mu.g of TG administered to each rat, 1 injection per week, and 4 consecutive weeks as a booster. The molding is completed by the end of week 8. After molding: one rat is selected from the model building group and the normal control group respectively, and detection is carried out after the sacrifice. If the rat has serum TPOAb and TGAb abnormality or one of the TPOAb and TGAb abnormality, and the thyroid tissue of the rat shows inflammation change, the model building is considered to be successful. The hair of the projection area of the thyroid gland before neck is removed from the modeled rat, and the rat is randomly divided into a model control group (10 animals) and a traditional Chinese medicine treatment group (10 animals) according to the body quality.
In the traditional Chinese medicine treatment group, the ointment obtained in the embodiment 1 is locally and externally applied to the anterior cervical thyroid projection region on the 15 th day after the model building is finished, kept for 30min, and cleaned with clear water after 15min. The medicine is administered 1 time daily for 42 days. All animals were sacrificed after blood samples were drawn at the end of week 15 and the thyroid glands were removed.
Material taking and index detection:
serum TGAb, TPOAb, IL-10, IFN-. Gamma.content treatment day 42, each group of experimental rats was subjected to abdominal aorta bleed and then sacrificed. The blood sample is centrifuged at 1500r/min to obtain serum.
TGAb, TPOAb, IL-10, IFN-. Gamma.titers in serum were determined using ELISA methods.
Thyroid tissue pathological change rat thyroid tissue is taken, fixed by 10% formaldehyde, embedded by conventional paraffin and sliced, and pathological morphological change and pathological grading index of the thyroid tissue are observed under a light microscope after HE staining.
The lymphocyte infiltration indexes are respectively 1, 2, 3 and 4 when the lymphocyte infiltration is less than 10 percent, 10 to 40 percent, 40 to 80 percent and more than 80 percent.
The statistical method comprises the following steps: the data were analyzed using SPSS19.0 statistical software. Measure data to
Showing that the values before and after treatment are compared with self control and group control, and adopting t test; the thyroid tissue lymphatic infiltration indexes of the rats in each group are compared and variance analysis is adopted. The difference is statistically significant when P is less than 0.05.
As a result: compared with the normal control group, the influence on the contents of rat serum TGAb, TPOAb, IL-10 and IFN-gamma is obviously improved in the serum TGAb and TPOAb concentrations of the model control group and the traditional Chinese medicine treatment group (P is less than 0.01), which indicates that the model building is successful. Compared with the model control group, the concentration of the serum TPOAb and the TGAb of the traditional Chinese medicine treatment group is reduced (P is less than 0.01). Compared with a normal control group, the serum IL-10 level of the model control group and the traditional Chinese medicine treatment group is reduced (P is less than 0.01); the IL-10 level of the traditional Chinese medicine treatment group is higher than that of the model control group (P is less than 0.01). Compared with a normal control group, the IFN-gamma level of the model control group and the IFN-gamma level of the traditional Chinese medicine treatment group are obviously increased (P is less than 0.01); compared with the model control group, the IFN-gamma level of the traditional Chinese medicine treatment group is reduced (P is less than 0.01). See Table 1
Table 1 comparison of serum TGAb, TPOAb, IL-10, IFN- γ content for each group (n =10,
)
| group of | TPOAb(IU/ml) | TGAb(IU/ml) | IL-10(ng/L) | IFN-γ(ng/L) |
| Normal control group | 2.12±0.99 | 7.41±2.47 | 25.02±3.02 | 120.98±30.30 |
| Model control group | 7.97±1.62 * | 29.66±5.44 * | 6.09±2.14 * | 760.41±103.71 * |
| Control group of traditional Chinese medicine | 3.07±1.65 *# | 12.14±4.33 *# | 13.91±4.42 #* | 358.14±169.48 *# |
The effect on the inflammation score of rats was increased in the model control group and the drug-treated group compared with the normal control group (P < 0.01). Compared with the model control group, the level of the inflammation score of the traditional Chinese medicine treatment group is reduced (P is less than 0.01). See table 2, fig. 1.
Table 2 comparison of inflammation scores for each group (n =10,
minute)
| Group of | Inflammation scoring |
| Normal control group | 1.00±0.00 |
| Model control group | 3.70±0.48 * |
| Control group of traditional Chinese medicine | 2.80±0.97 *# |
Injection, compared with normal control group, P is less than 0.01; compared with the model control group, # P < 0.01
Example 3
Clinical experiments are as follows:
the 65 cases of inclusion were HT patients in endocrinology visits. Patients were randomized into 33 treatment groups and 32 control groups using the random number table method. The treatment groups were 18 men and 15 women; age 22-69 years, mean (56.97 ± 11.26) years; the disease course is 1-9 years, and the average (3.31 +/-1.99) years; the number of cases of hyperthyroidism, hypothyroidism and normality is 7, 12 and 14, respectively. Control group 18 men and 14 women; the age is 24-69 years, and the average (56.93 +/-9.96) years; the disease course is 1-7 years, and the average (3.53 +/-2.00) years; the cases of hyperthyroidism, hypothyroidism and normality are 8, 14 and 10 cases respectively. The general data comparison of 2 patients is not statistically significant (P > 0.05), and is comparable.
The ointment obtained in example 1 was topically applied to the projected area of the anterior cervical thyroid gland, kept for 30min, and washed with clear water after 15min. The patient is instructed by the physician to complete the procedure, e.g., to immediately discontinue the treatment if a local skin allergy occurs. The treatment course is 6 months and 1 time per day.
Observation indicator and method
(1) Observing clinical symptom scores before and after treatment, including neck discomfort, dysphoria, irritability, debilitation, anorexia and amnesia, and respectively counting 1, 2 and 3 points according to the mild, medium and heavy symptoms; (2) serum TGAb, TPOAb levels were measured before and after treatment.
Analysis was performed using SPSS15.0 statistical software. Measure data to
Showing that the comparison among groups adopts t test; the data of the counting is as follows 2 And (6) checking. P < 0.05 indicates that the difference is statistically significant.
The experimental results are as follows:
compared with the pre-treatment, the scores of neck discomfort, irritability, hypodynamia, inappetence and amnesia symptoms of the 2 groups of patients after the treatment are all reduced (P is less than 0.05 and less than 0.01), and the comparative difference among the groups has statistical significance (P is less than 0.05 and P is less than 0.01), which is shown in a table 3.
Table 3: comparison of clinical symptom scores before and after treatment in group 2 HT patients: (
Minute)
Note: compared with the group before treatment, the P is less than 0.05 and the P is less than 0.01; compared with the control group after treatment, the delta-P is less than 0.05, and the delta-P is less than 0.01.
Compared with the treatment group, the TGAb and TPOAb are reduced after the treatment (P is less than 0.05), and the difference has statistical significance compared with the control group (P is less than 0.01), and the difference is shown in a table 4.
Table 4: comparison of TGAb and TPOAb levels before and after treatment in group 2 HT patients: (
IU/mL)
The total effective rate of the traditional Chinese medicine syndrome curative effect of the treatment group is 81.82% (27/33), the control group is 65.63% (21/32), and the treatment group is better than the control group (P is less than 0.01), as shown in Table 5.
Table 5:2 groups of HT patients with the syndrome curative effect comparison (example)
| Group of | Number of examples | Clinical recovery | Show effect | Is effective | Invalidation |
| Treatment group | 33 | 0 | 6 | 21 | 6 |
| Control group | 32 | 0 | 2 | 19 | 11 |
The total effective rate of clinical effect of the treatment group is 84.85% (28/33), the control group is 71.88% (23/32), and the treatment group is better than the control group (P < 0.05), as shown in Table 6.
Table 6: comparison of clinical efficacy in group 2 HT patients (example)
| Group of | Number of examples | Show effect | Is effective | Invalidation |
| Treatment group | 33 | 0 | 28 | 5 |
| Control group | 32 | 0 | 23 | 9 |
The experimental result shows that the traditional Chinese medicine syndrome score of the 2 groups is improved compared with that before treatment, the treatment group is superior to a control group (P is less than 0.05, P is less than 0.01), the levels of serum TPOAb and TGAb are reduced compared with that before (P is less than 0.05), and the traditional Chinese medicine syndrome curative effect and clinical curative effect treatment groups are superior to the control group (P is less than 0.01, P is less than 0.05). The prescription of the invention is shown to effectively reduce the index of the thyroid autoimmune antibody and improve the curative effect.
In the description herein, references to the description of "one embodiment," "an example," "a specific example" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Claims (5)
1. The neck-applied medicine for the autoimmune thyroid diseases is characterized by comprising the following raw materials in parts by mass: 25 to 35 portions of indigo naturalis, 25 to 35 portions of peach kernel, 15 to 25 portions of borneol, 5 to 15 portions of mirabilite, 25 to 35 portions of herba lycopi and 25 to 35 portions of dandelion.
2. The neck-applied medicine for the autoimmune thyroid diseases according to claim 1, which is characterized by comprising the following raw materials in parts by mass: 30 parts of indigo naturalis, 30 parts of peach kernel, 20 parts of borneol, 10 parts of mirabilite, 30 parts of herba lycopi and 30 parts of dandelion.
3. A preparation process of a neck-applied medicine for autoimmune thyroid diseases is characterized by comprising the following steps:
step1: taking the raw materials of the medicinal materials according to the proportion, processing the raw materials into fine powder and mixing the fine powder, wherein the borneol is independently ground into fine powder;
step2: heating adjuvants to 120 deg.C, filtering, and cooling to 60 deg.C at room temperature; mixing the auxiliary materials with the medicinal raw materials in a weight ratio of 1;
step3: adding the fine powder mixed in the Step1 into the cooling auxiliary materials in the Step3, and uniformly stirring the mixture until the mixture is semi-solidified paste.
4. The preparation process of the neck applied medicine for the autoimmune thyroid disease as claimed in claim 3, wherein the adjuvant comprises sesame oil.
5. The neck application medicine for the autoimmune thyroid diseases according to any one of claims 1 to 2, which discloses an application of the neck application medicine for the autoimmune thyroid diseases in the technical field of treatment medicines for hashimoto thyroiditis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211243083.8A CN115531450A (en) | 2022-10-11 | 2022-10-11 | Neck application medicine for autoimmune thyroid disease and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211243083.8A CN115531450A (en) | 2022-10-11 | 2022-10-11 | Neck application medicine for autoimmune thyroid disease and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115531450A true CN115531450A (en) | 2022-12-30 |
Family
ID=84732895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211243083.8A Pending CN115531450A (en) | 2022-10-11 | 2022-10-11 | Neck application medicine for autoimmune thyroid disease and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115531450A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524156A (en) * | 2015-01-26 | 2015-04-22 | 黑龙江中医药大学 | Traditional Chinese medicine cataplasma for treating autoimmune thyroiditis |
| CN110179917A (en) * | 2019-05-15 | 2019-08-30 | 上海市嘉定区中医医院 | It is a kind of for treating the Chinese medicine composition of the swollen point application of Hashimoto's thyroiditis cases |
-
2022
- 2022-10-11 CN CN202211243083.8A patent/CN115531450A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524156A (en) * | 2015-01-26 | 2015-04-22 | 黑龙江中医药大学 | Traditional Chinese medicine cataplasma for treating autoimmune thyroiditis |
| CN110179917A (en) * | 2019-05-15 | 2019-08-30 | 上海市嘉定区中医医院 | It is a kind of for treating the Chinese medicine composition of the swollen point application of Hashimoto's thyroiditis cases |
Non-Patent Citations (1)
| Title |
|---|
| 张毅等: "外用青黛治疗桥本甲状腺炎疗效及其对甲状腺自身免疫性抗体的影响", 《中国中医药信息杂志》, vol. 21, no. 10, pages 24 - 27 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qizilbash | In-situ and microinvasive adenocarcinoma of the uterine cervix: a clinical, cytologic and histologic study of 14 cases | |
| CN111407783B (en) | Application of penthorum chinense pursh in preparation of medicine for treating high proteinuria | |
| CN109453188B (en) | Application of sandworm polysaccharide in preparation of medicine for preventing and treating osteoporosis | |
| CN106822377B (en) | Compound osteitis cataplasm patch and preparation method thereof | |
| CN104491661A (en) | Traditional Chinese medicine composition used for treating prostatitis or benign prostatic hyperplasia | |
| CN115531450A (en) | Neck application medicine for autoimmune thyroid disease and preparation process thereof | |
| CN1207022C (en) | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing | |
| CN104147180B (en) | Pharmaceutical composition for the treatment of immunologic thrombocytopenic purpura and preparation method thereof | |
| CN114939150A (en) | Traditional Chinese medicine emulsifiable paste for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof | |
| CN107213426B (en) | Chinese patent medicine for treating mammary gland diseases and preparation method thereof | |
| CN110123868B (en) | Application of scorpion-containing traditional Chinese medicine composition in preparation of medicine for treating rheumatoid arthritis bone erosion | |
| CN101554386B (en) | Medicine composition for curing hepatic disease and preparation method thereof | |
| CN111358833A (en) | Prunella vulgaris extract and application thereof in preparation of medicines for treating thyroid diseases | |
| CN1134298A (en) | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy | |
| US4212857A (en) | Method for stimulating the production of immunoglobulin and total complement | |
| CN118001323B (en) | Traditional Chinese medicine composition for preventing and treating anxiety disorder and preparation method and application thereof | |
| CN109248269A (en) | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands | |
| CN115708859B (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method thereof | |
| CN115521962B (en) | Rice polypeptide composition and preparation method and application thereof | |
| CN116327885B (en) | Pharmaceutical composition for preventing and treating thyroid nodule | |
| CN115814040B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN115444917B (en) | Traditional Chinese medicine composition and traditional Chinese medicine cream for treating eczema, and preparation methods and application thereof | |
| CN108323750A (en) | A kind of active constituent and its extracting method and application with liver protection | |
| CN107137456A (en) | It is a kind of to treat medicine of chronic osteomyelitis and its preparation method and application | |
| CN111803545A (en) | Anti-inflammatory traditional Chinese medicine compound aqueous extract, pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221230 |
|
| RJ01 | Rejection of invention patent application after publication |